Gilead execs tick off its three top areas of M&A interest

Now that Gilead ($GILD) faces increased competition for its goliath share of the U.S. hep C market with Merck's ($MRK) fresh arrival on the scene, the Big Biotech is keeping a mental checklist of potential new collaborations and acquisitions that might help rev up some added excitement for the company's shares. In its review of annual numbers on Tuesday night, Gilead's John Milligan--soon to be CEO--cited three key areas of interest: oncology, inflammatory diseases and liver diseases. Story

Suggested Articles

Bayer's finerenone beat placebo at slowing kidney disease and cut the risk of heart attacks and strokes in diabetic kidney disease patients.

The National Institute of Allergy and Infectious Diseases is launching a new clinical trials network for COVID-19.

While Sanofi is looking to move more of its R&D in-house, there is still room for deals, and today it’s penned a big one with Fierce 15 winner Kymera